Folimycin (concanamycin A) inhibits LPS-induced nitric oxide production and reduces surface localization of TLR4 in murine macrophages

Innate Immunity

Volumn 14, Issue 1, 2008, Pages 13-24

  Eswarappa, Sandeepa M ^a   Basu, Nirmalya ^a   Joy, Omana ^a   Chakravortty, Dipshikha ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Folimycin; LPS; Nitric oxide; TLR4

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BACTERIUM LIPOPOLYSACCHARIDE; CONCANAMYCIN A; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; NITRIC OXIDE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ARTICLE; CELL PH; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SELECTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GOLGI COMPLEX; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR OCCUPANCY; SIGNAL TRANSDUCTION; ANIMAL EXPERIMENT; DRUG MECHANISM; MACROPHAGE FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT;

ANIMALS; CELL CULTURE TECHNIQUES; DOWN-REGULATION; DRUG ANTAGONISM; ENZYME INHIBITORS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GOLGI APPARATUS; LIPOPOLYSACCHARIDES; MACROLIDES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MUTAGENESIS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROTON-TRANSLOCATING ATPASES; TOLL-LIKE RECEPTOR 4;

MURINAE; NEGIBACTERIA;

EID: 59649108420     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425907087349     Document Type: Article

References (50)

1. Annane D., Bellissant E., Cavaillon J-M. Septic shock. Lancet 2005; 365: 63-78.
2. Medzhitov R., Preston-Hurlburt P., Janeway Jr CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-397.
3. Poltorak A., He X., Smirnova I. et al. Defective LPS signaling in C3H/ HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998; 282: 2085-2088.
4. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-1433.
5. Shimazu R., Akashi S., Ogata H. et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189: 1777-1782.
6. Nagai Y., Akashi S., Nagafuku M. et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002; 3: 667-672.
7. Hoshino K., Takeuchi O., Kawai T. et al. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749-3752.
8. Alderton WK, Cooper CE, Knowles RG Nitric oxide synthases: Structure, function and inhibition. Biochem J 2001; 357: 593-615.
9. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci 2004; 75: 639-653.
10. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2: 907-916.
11. Fitzgerald KA, Chen ZJ Sorting out Toll signals. Cell 2006; 125: 834-836.
12. Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene 2006; 25: 6758-6780.
13. Drose S., Bindseil KU, Bowman EJ, Siebers A., Zeeck A., Altendorf K. Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosine triphosphatases. Biochemistry 1993; 32: 3902-3906.
14. de Bouteiller O., Merck E., Hasan UA et al. Recognition of double-stranded RNA by human Toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem 2005; 280: 38133-38145.
15. Lee J., Chuang TH, Redecke V. et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003; 100: 6646-6651.
16. Rutz M., Metzger J., Gellert T. et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 2004; 34: 2541-2550.
17. Yilla M., Tan A., Ito K., Miwa K., Ploegh HL Involvement of the vacuolar H(+)-ATPases in the secretory pathway of HepG2 cells. J Biol Chem 1993; 268: 19092-19100.
18. Weisz OA Acidification and protein traffic. Int Rev Cytol 2003; 226: 259-319.
19. Mellman I., Fuchs R., Helenius A. Acidification of the endocytic and exocytic pathways. Annu Rev Biochem 1986; 55: 663-700.
20. Muroi M., Shiragami N., Nagao K., Yamasaki M., Takatsuki A. Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi apparatus. Cell Struct Funct 1993; 18: 139-149.
21. Muroi M., Takasu A., Yamasaki M., Takatsuki A. Folimycin (concanamycin A), an inhibitor of V-type H(+)-ATPase, blocks cell-surface expression of virus-envelope glycoproteins. Biochem Biophys Res Commun 1993; 193: 999-1005.
22. 15N]-nitrate in biological fluids. Anal Biochem 1982; 126: 131-138.
23. Muroi M., Shiragami N., Takatsuki A. Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase. Biochem Biophys Res Commun 1994; 205: 1358-1365.
24. Hong J., Nakano Y., Yokomakura A. et al. Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells. J Pharmacol Exp Ther 2006; 319: 672-681.
25. Drouet C., Shakhov AN, Jongeneel CV Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-alpha promoter in primary macrophages. J Immunol 1991; 147: 1694-1700.
26. Seog DH SS33410, an inhibitor of V-ATPase, blocks intracellular protein transport of the VSV-G protein in the Golgi compartment. Biosci Biotechnol Biochem 2003; 67: 2591-2597.
27. Seog DH, Yamasaki M., Takatsuki A. SS33410, an inhibitor for inflammation, blocks the intracellular transport of VSV G glycoprotein in BHK cells. Biochem Biophys Res Commun 1994; 199: 1073-1080.
28. Akashi S., Shimazu R., Ogata H. et al. Cell surface expression and lipopolysaccharide signaling via the Toll-like receptor 4--MD-2 complex on mouse peritoneal macrophages. J Immunol 2000; 164: 3471-3475.
29. Nomura F., Akashi S., Sakao Y. et al. Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface Toll-like receptor 4 expression. J Immunol 2000; 164: 3476-3479.
30. Gustafson CE, Katsura T., McKee M., Bouley R., Casanova JE, Brown D. Recycling of AQP2 occurs through a temperature- and bafilomycin-sensitive trans-Golgi-associated compartment. Am J Physiol 2000; 278: F317-F326.
31. Palokangas H., Metsikko K., Vaananen K. Active vacuolar H+-ATPase is required for both endocytic and exocytic processes during viral infection of BHK-21 cells. J Biol Chem 1994; 269: 17577-17585.
32. Robinson DG, Albrecht S., Moriysu Y. The V-ATPase inhibitors concanamycin A and bafilomycin A lead to Golgi swelling in tobacco BY-2 cells. Protoplasma 2004; 224: 255-260.
33. Zhang X., Morrison DC Lipopolysaccharide-induced selective priming effects on tumor necrosis factor α and nitric oxide production in mouse peritoneal macrophages. J Exp Med 1993; 177: 511-516.
34. Zhang X., Morrison DC Pertussis toxin-sensitive factor differentially regulates lipopolysaccharide-induced tumor necrosis factor-alpha and nitric oxide production in mouse peritoneal macrophages. J Immunol 1993; 150: 1011-1018.
35. Hirohashi N., Lei MG, Morrison DC LPS pretreatment of mouse peritoneal macrophages differentially modulates TNF-α and iNOS expression. J Endotoxin Res 1999; 5: 251-260.
36. Goldfeld AE, Doyle C., Maniatis T. Human tumor necrosis factor α gene regulation by virus and lipopolysaccharide. Proc Natl Acad Sci USA 1990; 87: 9769-9773.
37. Haas JG, Baeuerle PA, Riethmuller G., Ziegler-Heitbrock HWL. Molecular mechanisms in down-regulation of tumor necrosis factor expression. Proc Natl Acad Sci USA 1990; 87: 9563-9567.
38. Schapiro FB, Grinstein S. Determinants of the pH of the Golgi complex. J Biol Chem 2000; 275: 21025-21032.
39. Presley JF, Mayor S., McGraw TE, Dunn KW, Maxfield FR Bafilomycin A1 treatment retards transferrin receptor recycling more than bulk membrane recycling. J Biol Chem 1997; 272: 13929-13936.
40. Tawfeek HA, Abou-Samra AB Important role for the V-type H(+)-ATPase and the Golgi apparatus in the recycling of PTH/PTHrP receptor. Am J Physiol 2004; 286: E704-E710.
41. Palokangas H., Ying M., Vaananen K., Saraste J. Retrograde transport from the pre-Golgi intermediate compartment and the Golgi complex is affected by the vacuolar H+-ATPase inhibitor bafilomycin A1. Mol Biol Cell 1998; 9: 3561-3578.
42. Johnson LS, Dunn KW, Pytowski B., McGraw TE Endosome acidification and receptor trafficking: Bafilomycin A1 slows receptor externalization by a mechanism involving the receptor's internalization motif. Mol Biol Cell 1993; 4: 1251-1266.
43. da Silva Correia J., Ulevitch RJ MD-2 and TLR4 N-linked glycosylations are important for a functional lipopolysaccharide receptor. J Biol Chem 2002; 277: 1845-1854.
44. Ohnishi T., Muroi M., Tanamoto K. N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for Toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide. J Immunol 2001; 167: 3354-3359.
45. Stelter F., Pfister M., Bernheiden M. et al. The myeloid differentiation antigen CD14 is N- and O-glycosylated. Contribution of N-linked glycosylation to different soluble CD14 isoforms. Eur J Biochem 1996; 236: 457-464.
46. Kellokumpu S., Sormunen R., Kellokumpu I. Abnormal glycosylation and altered Golgi structure in colorectal cancer: Dependence on intra-Golgi pH. FEBS Lett 2002; 516: 217-224.
47. Annane D., Sanquer S., Sebille V. et al. Compartmentalised inducible nitric-oxide synthase activity in septic shock. Lancet 2000; 355: 1143-1148.
48. Han X., Fink MP, Yang R., Delude RL Increased iNOS activity is essential for intestinal epithelial tight junction dysfunction in endotoxemic mice. Shock 2004; 21: 261-270.
49. Nava E., Palmer RM, Moncada S. Inhibition of nitric oxide synthesis in septic shock: How much is beneficial? Lancet 1991; 338: 1555-1557.
50. Lopez A., Lorente JA, Steingrub J. et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32: 21-30.